ArticleMolecules (Basel, Switzerland)2026
Oral Food-Derived Proanthocyanidins as Immunostimulants: Enhanced Vaccine Immunogenicity via Host Immune Modulation in a Murine CSFV Model.
Article in Molecules (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Traditional injectable vaccine adjuvants are limited by local granulomatous reactions, chronic inflammation, and reduced compliance, creating an urgent need for safe, host-directed strategies to enhance vaccine immunogenicity. Proanthocyanidins (PACs)-natural polyphenols abundant in grapes, cocoa, and tea-are food-derived bioactive compounds with antioxidant, anti-inflammatory, and immunomodulatory activities, positioning them as attractive candidates for oral immunostimulants. Using classical swine fever virus (CSFV), a Pestivirus within the Flaviviridae that shares conserved genomic and immunological features with human pathogens such as hepatitis C and dengue virus, we systematically evaluated oral PACs (15, 30, and 60 mg/kg/d) combined with attenuated live or subunit CSFV vaccines in mice. PACs were well tolerated across the full dose range, with no impact on body weight or major organs, while selectively increasing the splenic index-suggesting spleen-targeted immune activation without systemic inflammation. Compared with vaccine alone, the moderate dose (30 mg/kg/d) produced the strongest immunostimulation, particularly with the subunit vaccine: peak antigen-specific IgG titer reached 1:409,600, a 4-fold increase versus 1:102,400 for subunit alone and exceeding the 3.4-fold gain observed with the attenuated vaccine. IgG2a and IgG2b rose by 199.4% and 269.1%, respectively, alongside coordinated elevations of Th1 (IL-2 +160.6%, IFN-γ +91.9%) and Th2 (IL-4, IL-10) cytokines, enhanced B- and T-lymphocyte proliferation, and expansion of CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.